Orhan Turan/iStock via Getty Images
Obesity drug developers Structure Therapeutics (NASDAQ:GPCR) and Metsera (NASDAQ:MTSR) recorded sharp gains alongside Eli Lilly (NYSE:LLY) on Thursday after the Indiana-based pharma giant reported Phase 3 data for its oral GLP-1 agonist orforglipron in type 2 diabetes.
While LLY said